Clinical Trials · NCT00696657
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 415
- Start date
- Jun 2008
- Locations
- 77 sites, 14 countries
- Primary endpoint
- HbA1c